1. Search Result
Search Result
Results for "

| DGK-zeta inhibitor

" in MedChemExpress (MCE) Product Catalog:

79

Inhibitors & Agonists

10

Peptides

7

Natural
Products

17

Recombinant Proteins

3

Isotope-Labeled Compounds

15

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-135898

    DGK Inflammation/Immunology Cancer
    DGK-IN-1 is a DGK inhibitor (DGKa/DGKz IC50: 0.65/0.25 μM). DGK-IN-1 is a T cell activator that can be used in cancer and viral infection research .
    DGK-IN-1
  • HY-156574

    DGK Cancer
    DGKζ-IN-4 is a DGK-zeta inhibitor. DGKζ-IN-4 can be used as an active component of pharmaceutical compositions. DGKζ-IN-4 is used to treat cancers associated with immune cell activation or cancers resistant to anti-PD-1 antibody/anti-PD-11 antibody treatment .
    DGKζ-IN-4
  • HY-156573

    DGK Cancer
    DGKα/ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα/ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor .
    DGKα/ζ-IN-1
  • HY-156572

    DGK Cancer
    DGKζ-IN-3 is a DGK-zeta-inhibitor. DGKζ-IN-3 is used in liquid and solid cancer and other diacylglycerol kinase zeta (DGK-ζ) regulation of diseases .
    DGKζ-IN-3
  • HY-164905

    DGK Cancer
    DGK-IN-8 (Example 34) is a DGK inhibitor, with IC50 of ≤ 20 nM for DGKα and ζ. DGK-IN-8 can be used for cancer research .
    DGK-IN-8
  • HY-178327

    DGK Interleukin Related Inflammation/Immunology Cancer
    DGKα/ζ-IN-2 is a potent, orally active and selective dual DGKα/ζ inhibitor with IC50 values of 23 nM (DGKα) and 1.2 nM (DGKζ). DGKα/ζ-IN-2 exhibits selectivity over other DGK isoforms, such as DGKβ and DGKγ. DGKα/ζ-IN-2 shows robust and dose-dependent immune activation in the presence of antigen presentation in an OT-1 murine model. DGKα/ζ-IN-2 can be used for antitumor immunity .
    DGKα&ζ-IN-2
  • HY-170427

    DGK Inflammation/Immunology
    DGKζ-IN-10 (compound 349) is a DGKζ inhibitor, with an IC50 ≤200 nM .
    DGKζ-IN-10
  • HY-170426

    DGK Inflammation/Immunology
    DGKζ-IN-9 (compound 73) is a DGKζ inhibitor, with an IC50 ≤200 nM .
    DGKζ-IN-9
  • HY-160123

    DGK Cancer
    DGKζ-IN-5 is a DGKζ inhibitor (WO2023125681A1; compound A27a) .
    DGKζ-IN-5
  • HY-169318

    DGK Interleukin Related Inflammation/Immunology Cancer
    DGKζ-IN-7 (compound 97) is an oral active DGKζ inhibitor with the IC50 of 33.4 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .
    DGKζ-IN-7
  • HY-169317

    DGK Interleukin Related Inflammation/Immunology Cancer
    DGKζ-IN-6 (compound 40) is an oral active DGKζ inhibitor with the IC50 of 45.5 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .
    DGKζ-IN-6
  • HY-P1372

    PKC Others
    PKC ζ pseudosubstrate, a PKC ζ inhibitor peptide, can be attached to cell permeabilization vector peptide .
    PKC ζ pseudosubstrate
  • HY-149874

    DGK Inflammation/Immunology Cancer
    BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50 of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research .
    BMS-502
  • HY-123979
    ζ-Stat
    2 Publications Verification

    NSC37044

    PKC Apoptosis Cancer
    ζ-Stat (NSC37044) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
    ζ-Stat
  • HY-129153

    Others Others
    Ganoderic acid ζ is a triterpene that can be isolated from the spores of Ganoderma lucidum .
    Ganoderic acid ζ
  • HY-N7807

    ζ2-Tocopherol

    Biochemical Assay Reagents Metabolic Disease
    (±)-5,7-Dimethyltocol (ζ2-Tocopherol) is an ester product.
    (±)-5,7-Dimethyltocol
  • HY-153793

    DGKζ-IN-1

    DGK Cancer
    Alcudacigib (DGKζ-IN-1) (compound 9) is an inhibitor of DGKζ. Alcudacigib can be used for research in cancer related to immunocyte activation or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody .
    Alcudacigib
  • HY-123979A
    ζ-Stat trisodium
    2 Publications Verification

    NSC37044 trisodium

    PKC Apoptosis Cancer
    ζ-Stat trisodium (NSC37044 trisodium) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat trisodium can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
    ζ-Stat trisodium
  • HY-149666

    DGK Cancer
    BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ) .
    BMS-496
  • HY-153343
    Veludacigib
    3 Publications Verification

    BAY 2965501

    DGK Cancer
    BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .
    Veludacigib
  • HY-100960

    Ethylene glycol dicaprylate; Ethylene glycol dioctanoate; Ethylenedioctanoate

    DGK Cardiovascular Disease
    Dioctanoylglycol (Ethylene glycol dicaprylate), a diacylglycerol analog, is a diacylglycerol kinase (DGK) inhibitor (Ki of 58 μM) .
    Dioctanoylglycol
  • HY-149667

    DGK Cancer
    BMS-332 is a dual DGKα/ζ lipid kinase inhibitor, with IC50s of 5 and 1 nM against DGKα and DGKζ, respectively. BMS-332 enhances the antigen-specific T cell response. BMS-332 reduces the viral load in the liver and spleen when combined with anti-PD-1 in chronic infection models. BMS-332 can be used for the study of T cell immune checkpoint strategy .
    BMS-332
  • HY-W750690

    Drug Derivative Others
    ζ-Carotene, a carotenoid, is a key intermediate in the carotenoid pathway. Carotenoids are important biological active, and may regulate cellular differentiation, growth control, photooxidative protection, cell membrane stability, photosynthesis, vision process and nutrition .
    ζ-Carotene
  • HY-153343A

    (S)-BAY 2965501

    DGK ERK Cancer
    (S)-BAY 2965501 is the left-handed isomer of BAY 2965501 (HY-153343). BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .
    (S)-Veludacigib
  • HY-159649

    DGK Cancer
    BMS-986408 is an orally active dual DGK α/ζ inhibitor that restores T cell-mediated anti-tumor immunity by enhancing T cell signaling .
    BMS-986408
  • HY-121638

    Apoptosis DGK Inflammation/Immunology Cancer
    CU-3 is the racemate of (5Z,2E)-CU-3. (5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC50 value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a Km value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .
    CU-3
  • HY-149665

    DGK Cancer
    BMS-684 is a selective DGKα inhibitor with an IC50 of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes .
    BMS-684
  • HY-171051

    DGK Others
    DGKα-IN-9 (example 298) is an inhibitor of DGKα .
    Pasodacigib
  • HY-175727

    DGK Cancer
    DGKα-IN-9 is a diacylglycerol kinase alpha (DGKα) inhibitor. DGKα-IN-9 demonstrates a tumor growth inhibition in MC38 or or CT26 mouse tumor model. DGKα-IN-9 can be used for the study of cancer .
    DGKα-IN-9
  • HY-120497

    PKC CDK Cancer
    PKCζ-IN-1 is a compound that inhibits PKCζ and CDK2, showing an IC50 value of 5.18 nM for PKCζ and 1.04 μM for CDK2, with significant selectivity of 200-fold. PKCζ-IN-1 can reduce the activity of CDK2 while inhibiting PKCζ.
    PKCζ-IN-1
  • HY-178062

    DGK Interleukin Related Cancer
    DGKα-IN-10 is an orally active and potent DGKα inhibitor with an IC50 of 0.27 nM. DGKα-IN-10 can induce IL-2 release and T cells proliferation. DGKα-IN-10 can be used for the research of cancer, such as colon cancer .
    DGKα-IN-10
  • HY-156576

    DGK Cancer
    DGKα-IN-6 is a DGKα inhibitor with the IC50 of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.
    DGKα-IN-6
  • HY-156577

    DGK Cancer
    DGKα-IN-7 is a DGKα inhibitor with the IC50 of 6.225 nM, extracted from patent WO2022271684 (compound 100). DGKα-IN-7 has the potential for cancer study.
    DGKα-IN-7
  • HY-156571

    DGK Cancer
    DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC50 of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.
    DGKα-IN-4
  • HY-156569

    DGK Inflammation/Immunology Cancer
    DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC50 of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-2
  • HY-156570

    DGK Inflammation/Immunology Cancer
    DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-3
  • HY-P1467

    5-Methionine-enkephalin amide

    Opioid Receptor Neurological Disease
    [Met5]-Enkephalin, amide is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.
    [Met5]-Enkephalin, amide
  • HY-P1467A

    5-Methionine-enkephalin amide TFA

    Opioid Receptor Neurological Disease
    [Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.
    [Met5]-Enkephalin, amide TFA
  • HY-156578

    DGK HIV Infection Cancer
    DGKα-IN-8 (Example 51) is a DGKα inhibitor (IC50=22.491 nM; EC50=0.256 nM). DGKα-IN-8 can be used to study cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection .
    DGKα-IN-8
  • HY-108355
    R59949
    1 Publications Verification

    PKC Cancer
    R59949 is a pan diacylglycerol kinase (DGK) inhibitor with an IC50 of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ. R59949 activates protein kinase C (PKC) by enhancing the levels of the endogenous ligand diacyl glycerol .
    R59949
  • HY-156575S

    Isotope-Labeled Compounds Others
    DGKα-IN-5 is a deuterium labeled compound.
    DGKα-IN-5
  • HY-P1399

    Myr-Pep2m

    PKC Neurological Disease
    Pep2m, myristoylated (Myr-Pep2m) is a cell-permeable peptide. Pep2m, myristoylated can disrupt the protein kinase ζ (PKMζ) downstream targets, N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .
    Pep2m, myristoylated
  • HY-P1399A

    Myr-Pep2m TFA

    PKC Neurological Disease
    Pep2m, myristoylated TFA (Myr-Pep2m TFA) is a cell-permeable peptide. Pep2m, myristoylated TFA can disrupt the protein kinase ζ (PKMζ) downstream targets, N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .
    Pep2m, myristoylated TFA
  • HY-156567

    DGK Metabolic Disease
    AMB639752 is a potent DGKα inhibitor. AMB639752 restores restimulation induced cell death (RICD) in SAP deficient lymphocytes by inhibiting DGKα in intact cells. AMB639752 can be used for X-linked lymphoproliferative disease 1(XLP-1) research .
    AMB639752
  • HY-P1391

    iGluR Others
    ZIP(Scrambled) is a scrambled control peptide for zeta inhibitory peptide (ZIP) .
    ZIP(Scrambled)
  • HY-P1391A

    PKC Others
    ZIP(Scrambled) TFA is a scrambled control peptide for zeta inhibitory peptide (ZIP) .
    ZIP(Scrambled) TFA
  • HY-121638A
    (5Z,2E)-CU-3
    1 Publications Verification

    Apoptosis DGK Cancer
    (5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC50 value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a Km value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .
    (5Z,2E)-CU-3
  • HY-162838

    Estrogen Receptor/ERR Others
    TCF199 is an allosteric stabilizer that stabilizes the 14-3-3/TAZ peptide interaction, binding to the 14-3-3ζ/E R α peptide and 14-3-3ζ/Chibby peptide. TCF199 has a Kd value of 122 μM for its interaction with 14-3-3/TAZ .
    TCF199
  • HY-N8301

    LL-Z 1272ζ

    Bacterial Infection
    Ilicicolin F is a fungal metabolite that has been found in Fusarium and has diverse biological activities. It inhibits T. vivax alternative oxidase and the E. coli ubiquinol oxidase cytochrome bo (IC50s=0.43 and 0.37 μM, respectively) but not the E. coli ubiquinol oxidase cytochrome bd (IC50=85 μM).2 Ilicicolin F is active against the fungi A. fumigatus and C. albicans (MICs=1.66-3.33 and 6.66-13.33 μg/mL, respectively). It is cytotoxic to HeLa cells with an EC50 value of 0.003 μg/mL.
    Ilicicolin F
  • HY-122949
    Momordicine I
    1 Publications Verification

    Apoptosis Autophagy DGK Mitochondrial Metabolism NO Synthase PI3K Akt Interleukin Related Src AMPK mTOR NF-κB c-Met/HGFR STAT Keap1-Nrf2 Reactive Oxygen Species (ROS) Oxidative Phosphorylation Endogenous Metabolite Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes .
    Momordicine I

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: